Nicotinamide Riboside (NR): What Human Trials Actually Show

By Erin Rose · Updated July 18, 2026 · Methodology

Educational overview — not medical advice. NR has no established RDA or upper limit, and no long-term (6-month+) human safety data at any dose. This statement has not been evaluated by the FDA. This product is not intended to diagnose, treat, cure, or prevent any disease.

As an Amazon Associate we earn from qualifying purchases. Only two NR products cleared our live-price verification — see why.

Start here

What NR is, and the regulatory story NMN doesn't have

Nicotinamide riboside (NR) is a form of vitamin B3 the body converts into NAD+, a coenzyme central to energy metabolism that declines with age. Unlike its sister NAD+ precursor NMN, NR is not a novel regulatory case: it has been marketed as a dietary supplement since before the FDA's 2016 New Dietary Ingredient cutoff, holds two separate NDI notifications, and received a self-affirmed GRAS notice (GRN 000635) covering its safety for general use. It has never been excluded from the legal definition of a dietary supplement and has never been pulled from Amazon — a genuinely different story from NMN, which was excluded in November 2022, delisted from Amazon by March 2023, and only reinstated in September 2025 after a lawsuit forced the FDA's hand. That contrast is documented in more depth on NMN vs. NR, and it matters here because it's the one place NR is unambiguously the stronger of the two compounds — not on efficacy, but on regulatory cleanliness.

The science is where the honesty has to work harder. Eight verified human trials make up NR's evidence base, spanning n=8 to n=40 and 21 days to 12 weeks. Every one of them measured NAD+ (blood, muscle, PBMCs, or brain tissue), and 7 of the 8 found it rose, often steeply and dose-dependently — the exception is Dollerup 2020's muscle substudy, which found no change in muscle NAD+ despite a drop in the NAMPT enzyme. But eight trials is a smaller, more modest evidence base than NMN's — consistent with how the live NMN vs. NR page already frames it — and NR's trial volume should not be read as proof of superior efficacy to NMN. It should be read as proof of one thing done reliably: raising NAD+.

Does it work? (the honest short version)

Unevenly, and the pattern matters more than any single result. NAD+ reliably rises — that's real, replicated pharmacology across every dose and population tested, from 100 mg single doses up to 2,000 mg/day sustained for 12 weeks. But five independent, non-industry-funded RCTs each tested a different functional or clinical endpoint downstream of that NAD+ rise, and each came back null or explicitly underpowered: blood pressure and arterial stiffness (Martens 2018), insulin sensitivity and whole-body metabolism (Dollerup 2018), skeletal-muscle mitochondrial function twice over (Dollerup 2020, Elhassan 2019), and heart-failure walk distance, ejection fraction, and quality of life (Wang 2022). The one partial exception, NADPARK, found a correlational "mild clinical improvement" signal in Parkinson's patients — but it's a 30-day, n=30, Phase I safety trial, never a proof that NR treats Parkinson's. The full pattern, trial by trial, is on the does-it-work page.

The buying problem: a near-duopoly, not a marketplace

Before publishing this cluster, we ran a live-price verification pass across the NR products commonly recommended online. Only two came back with a confirmed, currently buyable Amazon listing: Tru Niagen 300mg, the Niagen-branded ingredient behind Conze 2019's dose-response trial, and Thorne NiaCel 400, Thorne's own NR hydrogen malate form, NSF Certified for Sport. Several generic NR listings we checked were out of stock or had been delisted — a real, disclosable pattern tied to NR's history of composition-of-matter patent enforcement (see the best-overall page for the resolved 2021-2024 ChromaDex/Thorne litigation). That scarcity is the honest story, not a gap we've papered over with unverified products.

Safety

No serious adverse events have been reported across the dose range tested (100 mg to 2,000 mg/day) for up to 12 weeks. Conze 2019 is the dedicated safety citation: no flushing (a real practical advantage over plain niacin, which is well known to cause it), no significant adverse-event difference vs. placebo, no LDL elevation, no disruption of one-carbon metabolism. Two trials confirmed safety at the higher 2,000 mg tier in more clinically burdened populations (obese/insulin-resistant men, heart-failure patients), with normal safety labs throughout. Three gaps to state plainly: no human NR trial has run longer than 12 weeks, so there is no long-term (6-month+) safety data at any dose; there is no pregnancy or breastfeeding data at all; and unlike NMN, NR has not been flagged in the sources reviewed here with a theoretical nucleotide/cancer-cell-metabolism caution — that absence is not the same as an affirmative safety finding, so don't overclaim it either way. No RDA or upper limit exists for NR; Conze 2019's own language only says its findings "support the development of" a tolerable upper limit, which has not actually been established.

Frequently asked questions

Related guides

• NMN — the sister NAD+ precursor with the more volatile regulatory history
• NMN vs. NR — the full mechanistic and regulatory comparison
• CoQ10 — another mitochondrial-energy-adjacent supplement with its own absorption-form distinction
• Vitamin B12 — another "energy" supplement where the marketing outruns the deficiency-correction evidence

Sources